Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.2550 (-1.33%) ($9.2550 - $9.3500) on Wed. Apr. 6, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.36% (three month average) | RSI | 43 | Latest Price | $9.2550(-1.33%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.7% a day on average for past five trading days. | Weekly Trend | FOLD declines -1.2% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(63%) IWO(50%) IWC(47%) IWM(47%) XBI(44%) | Factors Impacting FOLD price | FOLD will decline at least -2.18% in a week (0% probabilities). VIXM(-26%) VXX(-12%) UUP(-10%) UNG(-9%) EDOC(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.18% (StdDev 4.36%) | Hourly BBV | -1 () | Intraday Trend | 0% | | | |
|
Resistance Level | $9.46 | 5 Day Moving Average | $9.45(-2.06%) | 10 Day Moving Average | $9.49(-2.48%) | 20 Day Moving Average | $9.46(-2.17%) | To recent high | -23.9% | To recent low | 17.4% | Market Cap | $2.39b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |